Loading
MWN109 1 / Overweight , Obesity / MWN109 2 · Phase 2 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 2 study comparing two dosing schedules (QD and QW) of MWN109 tablet in 71 non-diabetic overweight or obese participants over 24 weeks. No results are posted in this registry record; the study is currently active but not recruiting. The primary outcome is percentage change in body weight at week 24.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Overweight , Obesity; age from 18 Years; to 65 Years. Intervention: MWN109 Cohort 1; MWN109 Cohort 2. Compared with: MWN109 tablet once-weekly (QW) dosing. n = 71. 1 site: China.
This is a planned Phase 2 study comparing two dosing schedules (QD and QW) of MWN109 tablet in 71 non-diabetic overweight or obese participants over 24 weeks. No results are posted in this registry record; the study is currently active but not recruiting. The primary outcome is percentage change in body weight at week 24.
No results are reported in this registry record; outcome data and efficacy or safety findings are not available.
The source did not state who this applies to in practice.
Phase 2 registry record with no reported results; study is active but not yet recruiting or completed, describing a planned 24-week intervention in 71 participants.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07804797). This is a study registration, not published results. Lead sponsor: Shanghai Minwei Biotechnology Co., Ltd. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 71 participants (ACTUAL). Conditions: Overweight , Obesity. Interventions: DRUG: MWN109 1; DRUG: MWN109 2. Primary outcome measures: Percentage change in body weight compared to baseline after 24 weeks of drug administration , Baseline, Week 24. Brief summary: This study adopted a randomized, open-label design, aiming to preliminarily explore the weight-loss maintenance effect of MWN109 tablets when administered continuously for 24 weeks in non-diabetic overweight or obese participants. Participants who met the inclusion criteria were randomly assigned (1:1) to either the QD or QW administration group of MWN109 tablets, with the dose grouping in the MWN109-II-WL study serving as a random stratification factor. This study included a maximum screening period of 2 weeks, a 24-week treatment observation period, and a 2-week safety follow-up period, totaling 28 weeks. The primary endpoint was the percentage change in weight from baseline after 24 weeks of administration. The secondary endpoints included the change in weight from baseline after 24 weeks of administration, as well as the change in waist circumference from baseline.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.